Evaluating the health impact of a public-private partnership
- 12 June 2012
- journal article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (6) , 777-782
Abstract
The purpose of this article is to describe the RotaTeq(®) Nicaragua Partnership and the evaluation of the public health impact of the vaccine conducted by the partners, including the creation of a rotavirus surveillance program and a vaccine effectiveness assessment. The three main objectives of the partnership were to demonstrate that a new rotavirus vaccine could (1) be introduced rapidly in a developing country, (2) be successfully integrated into the existing vaccine delivery infrastructure, and (3) have a significant and measurable public health impact at the end of the 3-y program. The vaccine impact assessment required collaboration among partners with different areas of expertise, including the Nicaraguan Ministry of Health, Merck, local hospitals, government health clinics, laboratories, and a Technical Advisory Group. Through the partnership, RotaTeq(®) became available in a GAVI-eligible developing country, Nicaragua, in the same year it was approved in the United States. Vaccine coverage rapidly reached over > 90% of eligible Nicaraguan children. The impact assessment evaluated over 10,000 subjects and leveraged and enhanced the existing diarrheal surveillance infrastructure, ultimately providing the scientific community with some of the first real-world rotavirus vaccine effectiveness data from a developing country. The successful public-private partnership (PPP) was internationally recognized as a model for the rapid adoption of a new vaccine in a developing world setting. The model could be adapted to benefit other PPPs interested in demonstrating the impact of their own programs.Keywords
This publication has 10 references indexed in Scilit:
- Case-control Study of the Effectiveness of Vaccination With Pentavalent Rotavirus Vaccine in NicaraguaThe Pediatric Infectious Disease Journal, 2011
- Rotavirus disease burden, Nicaragua 2001–2005: defining the potential impact of a rotavirus vaccination programInternational Journal of Infectious Diseases, 2010
- The effect of rotavirus vaccine on diarrhoea mortalityInternational Journal of Epidemiology, 2010
- Association Between Pentavalent Rotavirus Vaccine and Severe Rotavirus Diarrhea Among Children in NicaraguaJAMA, 2009
- The Mectizan Donation Program: 20 years of successful collaboration — a retrospectivePathogens and Global Health, 2008
- Outbreak of rotavirus gastroenteritis with high mortality, Nicaragua, 2005Revista Panamericana de Salud Pública, 2008
- Determinanten für Reaktionen auf orale Impfstoffe in EntwicklungsländernAnnales Nestlé (Deutsche Ausg.), 2008
- Rotavirus vaccines: current prospects and future challengesThe Lancet, 2006
- Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus VaccineNew England Journal of Medicine, 2006
- Case-control studies of the effectiveness of vaccines: validity and assessment of potential biasThe Pediatric Infectious Disease Journal, 2004